|
Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy Clinical research trials and Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy. Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy clinical trial. Human subjects frequently get the finest healthcare available for their Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "M" Clinical Trials Conditions > Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy  Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy
Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy
For Condition: Communicable Diseases,Opportunistic Infections
Status: Completed
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: Patients are exposed to infectious agents regularly, regardless of their immunologic status. Traditionally clinicians have decided to institute prophylaxis based on epidemiologic factors, skin test (i.e. PPD), or immunologic parameters. A quantitative and specific method that is non-invasive, such as quantitative PCR, would be desirable to more precisely define those who would benefit from prophylaxis. Similarly, when patients develop disease and are being treated, quantitative, non-invasive techniques are needed to assess response to therapy. This project is designed to develop and test quantitative tests using blood, urine, or sputum samples.
Details: Patients are exposed to infectious agents regularly, regardless of their immunologic status. Traditionally clinicians have decided to institute prophylaxis based on epidemiologic factors, skin test (i.e. PPD), or immunologic parameters. A quantitative and specific method that is non-invasive, such as quantitative PCR, would be desirable to more precisely define those who would benefit from prophylaxis. Similarly, when patients develop disease and are being treated, quantitative, non-invasive techniques are needed to assess response to therapy. This project is designed to develop and test quantitative tests using blood, urine, or sputum samples.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Patients older than 18 years of age. Ability to give informed consent. No medical contraindication to phlebotomy. Epidemiologically at risk for tuberculosis or for an opportunistic infection. Patients who can identify a responsible health care provider as someone willing to provide clinical information and to receive medically important information.
Total Enrollment: 300
Location and Contact Information:
National Institute of Allergy and Infectious Diseases (NIAID)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 950176; 95-I-0176
Study Start Date: August 29, 1995
Record last reviewed: February 25, 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001477
Other Communicable Diseases Studies:
1. Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy
2. Vaccinia Immune Globulin in Treating or Preventing Vaccinal Infection
Related Studies:
Other Communicable Diseases Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy
|
|
|
|
|
|
|
|
